Risk modifiers for peripheral sensory neuropathy in HIV infection/AIDS
- 28 January 2004
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 11 (2) , 97-102
- https://doi.org/10.1046/j.1351-5101.2003.00713.x
Abstract
The objective of this study is to examine the risk factors associated with the development of sensory neuropathy in human immunodeficiency virus (HIV)-infected patients in 292 HIV+ patients recruited through a community-based sentinel survey. We determined the clinical and treatment factors associated with the presence of peripheral sensory neuropathy in HIV+ subjects at baseline examination, and at 1-year follow-up. Baseline examination was assessed with a logistic regression analysis controlling for age, education level, history of drug/alcohol use, and anti-retroviral treatment. The risk of developing new peripheral neuropathy at follow-up was determined using a Cox proportional hazard model analysis. At study entry, neuropathy (n=64) was associated with acquired immunodeficiency syndrome (AIDS), nucleoside analogue reverse transcriptase inhibitors (NRTI) (i.e. ddC), and history of alcohol abuse. After 1-year follow-up, the development of neuropathy was predicted by AIDS, age (older subjects), and NRTI use. These findings indicated that AIDS, age, alcohol abuse/dependence, and anti-retroviral medication use are important predictors of motor/sensory peripheral neuropathy in the HIV infection. The peripheral neurotoxic effect of anti-retroviral medication should be taken into account in the design of long-term therapies.Keywords
This publication has 23 references indexed in Scilit:
- Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infectionAIDS, 2000
- Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapyAIDS, 1999
- Neuromuscular function in HIV infectionAIDS, 1998
- Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cellsJournal of the Neurological Sciences, 1997
- Prevalence and predictors of depressive, anxiety and substance use disorders in HIV-infected and uninfected men: a longitudinal evaluationPsychological Medicine, 1997
- Neuropsychological abnormalities among HIV-infected individuals in a community-based sample.Neuropsychology, 1997
- Low-dose zalcitabine-related toxic neuropathyNeurology, 1996
- Low prevalence of neurological and neuropsychological abnormalities in otherwise healthy HIV‐1–infected individuals: Results from the multicenter AIDS cohort studyAnnals of Neurology, 1989
- Declining incidence of AIDS dementia complex after introduction of zidovudine treatment.BMJ, 1989
- Neurological complications of acquired immune deficiency syndrome: Analysis of 50 patientsAnnals of Neurology, 1983